NCT05945823 2025-12-29
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT03698461 2024-01-31
CLIMB
Asan Medical Center
Phase 2 Completed
NCT06197438 2024-01-09
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT03222089 2018-03-27
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
Fujian Cancer Hospital
Phase 2 Withdrawn
NCT00865709 2014-12-11
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
Bayer
Phase 2 Completed